- ALK Inhibitors, a Pharmaceutical PerspectiveElena Ardini
Department of Cell Biology, Oncology, Nerviano Medical Sciences Milan, Italy
Front Oncol 2:17. 2012..Here we discuss the factors that led to such a rapid approval of a targeted agent, and we describe the second-generation compounds currently in development...
- Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapyE Ardini
Department of Cell Biology, Oncology, Nerviano Medical Sciences S r l, Viale Pasteur 10, 20014 Nerviano, Milan, Italy
Cancer Lett 299:81-94. 2010..In this review, we describe the various oncogenic forms of ALK, relevant clinical settings, and give a detailed overview of current drug discovery efforts in the field...